This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Coronavirus disease 2019 (COVID-19) is a viral infection with the novel severe acute
respiratory distress syndrome corona virus 2 (SARS-CoV-2). Until now, more than 670 …

Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …

Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Azvudine is recommended by Chinese health authorities for COVID‐19 treatment but has
not been tested in real‐world clinical studies. This study aimed to evaluate the real‐world …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …

Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …